FDA Approves Merck's Keytruda For Use In Lung Cancer
(Reuters) - The U.S. Food and Drug Administration granted accelerated approval for Merck & Co's immunotherapy, Keytruda, in patients with a form of lung cancer.
Keytruda and another similar treatment from Bristol-Myers Squibb Co called Opdivo block a protein called PD-1, whose natural function is to put checks on the immune system.
Wall Street analysts expect such drugs to capture combined annual sales of over $20 billion by 2020.
Keytruda was approved last year to treat patients with advanced melanoma.
@ 2012 Thomson Reuters. All rights reserved.
Join the Discussion